北京神州细胞生物技术集团股份公司（以下简称"公司"）第二届董事会第 十五次会议于 2025 年 4 月 25 日在公司会议室以现场及通讯方式召开，本次会议 的通知及相关材料于 2025 年 4 月 15 日通过电子邮件方式送达全体董事。本次会 议应出席董事 9 人，实际到会董事 9 人。本次会议由董事长谢良志博士主持，会 议的召集和召开程序符合《中华人民共和国公司法》《北京神州细胞生物技术集 团股份公司章程》（以下简称"《公司章程》"）以及其他有关法律法规、规范 性文件的规定。 二、董事会会议审议情况 经与会董事充分讨论，会议以投票表决方式审议通过了如下议案： （一）审议通过《关于公司 2024 年年度报告及其摘要的议案》 具体内容详见公司在上海证券交易所网站（www.sse.com.cn）披露的相关公 告。 表决结果：同意9票，反对0票，弃权0票。 证券代码：688520 证券简称：神州细胞 公告编号：2025-008 北京神州细胞生物技术集团股份公司 第二届董事会第十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承 ...

证券代码：688520 证券简称：神州细胞 公告编号：2025-010 北京神州细胞生物技术集团股份公司 关于2024年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 北京神州细胞生物技术集团股份公司（以下简称"公司"）截至 2024 年 12 月 31 日累计未分配利润为负值，根据《上市公司监管指引第 3 号—上市公司 现金分红》及《公司章程》等规定，2024 年度拟不进行现金分红，也不进行资 本公积金转增股本和其他形式的分配。 本次拟不进行利润分配的方案尚需提交公司 2024 年年度股东大会审议。 一、利润分配方案内容 经信永中和会计师事务所（特殊普通合伙）审计，截至2024年12月31日， 公司合并报表累计未分配利润为-3,818,000,173.03元，母公司报表累计未分配利 润为-425,319,746.80元，均为负值，不满足《上市公司监管指引第3号——上市 公司现金分红》以及《公司章程》等规定的现金分红条件。经公司第二届董事 会第十五次会议及第二届监事会第十四次会议审议通 ...

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.2400 | -0.8900 | 126.97 | -1.1900 | | 每股净资产（元） | -1.04 | -1.35 | 22.96 | -0.53 | | 每股公积金(元) | 6.54 | 6.47 | 1.08 | 6.4 | | 每股未分配利润(元) | -8.57 | -8.82 | 2.83 | -7.93 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 25.13 | 18.87 | 33.17 | 10.23 | | 净利润(亿元) | 1.12 | -3.96 | 128.28 | -5.19 | | 净资产收益率(%) | | | 0 | | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 35463.86万股，累计占流通股比： 79.65%，较上期变化： 282 ...

北京神州细胞生物技术集团股份公司 2024 年度 审计报告 | 索引 | 项码 | | --- | --- | | 审计报告 | 1-5 | | 公司财务报表 | | | 合并资产负债表 | 1-2 | | 母公司资产负债表 | 3-4 | | 合并利润表 | 5 | | 母公司利润表 | 6 | | 合并现金流量表 | 7 | | 母公司现金流量表 | 8 | | 合并股东权益变动表 | 9-10 | | 母公司股东权益变动表 | 11-12 | | 财务报表附注 | 13-98 | 事务所| 北京市东城区朝阳门北大街 8 号宫华大厦 A 座 9 层 胜系曲话· 9/F Block A. Fu Hua Mansion No 8 Chaovangmen Beidaiie Donacheng District. Beijing 100027. P.R.China +86 (010) 6554 7190 审计报告 XYZH/2025BJAA1B0445 北京神州细胞生物技术集团股份公司 北京神州细胞生物技术集团股份公司全体股东: 一、审计意见 我们审计了北京神州细胞生物技术集团股份公司(以下简称神州细胞公司)财务 ...

联系申话: 信永中和会计师事务所 北京市东城区朝阳门北大街 8 号富华大厦 A 座 9 层 9/F, Block A. Fu Hua Mansic lo.8. Chaoyangmen Beid Dongcheng District, Beijing 100027. P.R.China 北京神州细胞生物技术集团股份公司 2024 年 12 月 31 日 内部控制审计报告 - +86 (010) 6554 7190 内部控制审计报告 XYZH/2025BJAA1B0444 北京神州细胞生物技术集团股份公司 北京神州细胞生物技术集团股份公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计 了北京神州细胞生物技术集团股份公司(以下简称神州细胞公司)2024年12月 31日财 务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评 价指引》的规定,建立健全和有效实施内部控制,并评价其有效性是神州细胞公司董事 会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表审计意 ...

1、 专项审计报告 2、 附表 北京神州细胞生物技术集团股份公司 2024 年度 非经营性资金占用及其他关联资金往来的 专项说明 关于北京神州细胞生物技术集团股份公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 委托单位：北京神州细胞生物技术集团股份公司 审计单位：信永中和会计师事务所（特殊普通合伙） | 索引 | 页码 | | --- | --- | | 专项说明 | 1-2 | | 非经营性资金占用及其他关联资金往来情况汇总表 | | 联系电话: 北京市东城区朝阳门北大街 官永中和会计师事务所 telephone: 8 号富华大厦 A 座 9 层 9/F, Block A, Fu Hua Mansion No.8, Chaoyangmen Beidajie, Dongcheng District, Beijing, 100027, P.R.China ShineWing 传真: +86 (010) 6554 2288 关于北京神州细胞生物技术集团股份公司 2024 年度非经营性资金占用及其他关联资金往来的专项说明 XYZH/2025BJAA1B0441 北京神州细胞生物技术集团股 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥519.74 million, a decrease of 15.15% compared to ¥612.50 million in the same period last year[4] - Net profit attributable to shareholders was ¥63.77 million, down 14.06% from ¥74.20 million year-on-year[4] - The net profit after deducting non-recurring gains and losses dropped significantly by 84.98%, from ¥157.00 million to ¥23.58 million[4] - The net cash flow from operating activities was negative at -¥106.92 million, a decline of 161.23% compared to ¥174.61 million in the previous year[4] - Total operating revenue for Q1 2025 was CNY 519.74 million, a decrease of 15.1% compared to CNY 612.50 million in Q1 2024[17] - Net profit for Q1 2025 was CNY 63.94 million, down 14.0% from CNY 74.41 million in Q1 2024[18] - The company recorded a total profit of CNY 63.94 million in Q1 2025, with no income tax expenses reported[18] Research and Development - R&D investment totaled ¥185.37 million, representing a decrease of 24.18% from ¥244.48 million year-on-year[4] - R&D expenses accounted for 35.67% of operating revenue, down from 39.92% in the previous year[5] - Research and development expenses were CNY 177.81 million in Q1 2025, a decrease of 25.1% from CNY 237.33 million in Q1 2024[17] - The company is investing 50 million RMB in R&D for new technologies aimed at enhancing product efficiency[22] Assets and Liabilities - Total assets increased by 5.04% to ¥3.45 billion from ¥3.28 billion at the end of the previous year[5] - Current assets totaled RMB 1,611,064,341.24, up from RMB 1,460,622,848.37, indicating an increase of about 10.27%[14] - Total liabilities reached RMB 3,251,127,937.15, compared to RMB 3,149,055,574.41, reflecting an increase of approximately 3.25%[15] - The company's short-term borrowings rose to RMB 1,235,413,267.58 from RMB 1,077,987,553.63, indicating an increase of about 14.61%[14] - Non-current assets totaled RMB 1,838,541,502.94, slightly up from RMB 1,823,373,569.25, showing a marginal increase of about 0.83%[14] - The cash and cash equivalents decreased to RMB 302,866,339.99 from RMB 314,933,923.79, reflecting a decline of about 3.54%[12] Shareholder Information - Shareholders' equity attributable to shareholders rose by 44.97% to ¥204.26 million from ¥140.90 million at the end of the previous year[5] - The number of ordinary shareholders at the end of the reporting period was 11,178[8] - The company reported a decrease in retained earnings, with a balance of RMB -3,759,707,359.98 compared to RMB -3,818,000,173.03, indicating an improvement in the negative retained earnings by approximately 1.54%[15] Market Outlook and Strategy - The company provided a future outlook, projecting a revenue growth of 20% for the full year 2025[22] - New product launches are expected to contribute an additional 300 million RMB in revenue by Q3 2025[22] - Market expansion plans include entering two new international markets by the end of 2025[22] - The company is considering strategic acquisitions to enhance its market position, with a budget of 200 million RMB allocated for potential deals[22] - A new marketing strategy is set to increase brand awareness, targeting a 30% increase in customer engagement by Q4 2025[22] Operational Efficiency - The company aims to reduce operational costs by 10% through efficiency improvements in the next fiscal year[22] - The gross margin improved to 45%, up from 40% in the previous year[22] - The company experienced a significant decrease in cash inflow from sales, which was CNY 420.11 million in Q1 2025, down 32.9% from CNY 626.38 million in Q1 2024[20]

Financial Performance - The company achieved a total operating revenue of 2,512.71 million yuan, representing a year-on-year growth of 33.13%[3]. - The net profit attributable to shareholders of the listed company was 111.95 million yuan, with a net profit of 474.41 million yuan after deducting non-recurring gains and losses[3]. - The company's operating revenue for 2024 reached ¥2,512,708,141.32, representing a 33.13% increase compared to ¥1,887,349,306.40 in 2023[25]. - The net profit attributable to shareholders was ¥111,951,088.88 in 2024, a significant turnaround from a loss of ¥396,018,311.08 in 2023[25]. - The net cash flow from operating activities improved to ¥125,123,630.31 in 2024, compared to a negative cash flow of ¥383,369,058.67 in 2023[26]. - The company's total assets increased by 20.80% to ¥3,283,996,417.62 at the end of 2024, up from ¥2,718,536,171.39 in 2023[26]. - Basic earnings per share for 2024 were ¥0.24, a recovery from a loss of ¥0.89 per share in 2023[27]. - The net assets attributable to shareholders turned positive, reaching ¥140,896,888.73 at the end of 2024, compared to a negative net asset of ¥599,461,618.33 at the end of 2023[28]. - The company reported a total of ¥90,084,460.16 in government subsidies related to its normal business operations in 2024[33]. - The total non-recurring losses amounted to ¥362,459,499.73 in 2024, compared to ¥332,337,823.28 in 2023, indicating ongoing challenges in non-operational areas[33]. Research and Development - The company is in the process of developing new products, including the PD-1 monoclonal antibody drug and the CD20 monoclonal antibody drug[13]. - The company's total R&D investment for 2024 was 936.02 million yuan, focusing on clinical research for multiple products[39]. - The company obtained 16 new invention patent applications and 82 new invention patent authorizations during the reporting period[39]. - The company has established a high-efficiency, high-throughput technology platform for the research and production of biopharmaceuticals, with multiple products in various stages of clinical research[51]. - The company has developed a new series of recombinant protein vaccines for COVID-19 variants, with several products included in emergency use by the state[60]. - The company has multiple products in various clinical stages, including SCT650C for moderate to severe plaque psoriasis, which has initiated Phase II clinical trials[66]. - The company is conducting post-marketing clinical research for SCT800, a third-generation recombinant coagulation factor product, with a total investment of ¥25 million[103]. - The company has developed SCT1000, the world's first 14-valent HPV vaccine, which has completed Phase III clinical trials and shows promising immunogenicity and safety[84]. - The company has rapidly completed the preclinical development and production of 6 COVID-19 neutralizing antibodies and 10 recombinant protein vaccines since early 2020, demonstrating advanced R&D speed and efficiency[91]. Product Development and Market Strategy - The core product Anjain® had stable sales, reaching 1.89 billion yuan, an increase of 6.18% year-on-year[37]. - The sales revenue of three antibody products, including Anpingxi®, Anjairun®, and Anbeizhu®, exceeded 620 million yuan, a significant increase of 499.80%[37]. - The company successfully launched the drug Anyouping® for head and neck squamous cell carcinoma, expanding its product matrix in oncology[37]. - The company has signed agreements with over ten "Belt and Road" countries, including Indonesia and Brazil, to commercialize its product Anjain®[46]. - The company has submitted drug registration applications for Anjain® in Thailand and the Philippines, with approvals expected in December 2024 and March 2025 for Pakistan and Indonesia, respectively[46]. - The company has accelerated cooperation with "Belt and Road" countries for its biosimilar drugs Anjairun® and Anbeizhu®, with Anjairun®'s registration application submitted in Pakistan in September 2024 and approval expected in February 2025[47]. - The company is actively enhancing its compliance operations to mitigate legal and reputational risks, ensuring adherence to domestic and international regulations[48]. - The company is focused on developing treatments for malignant tumors, autoimmune diseases, infectious diseases, and genetic disorders[158]. Governance and Compliance - The company has received a standard unqualified audit report from the accounting firm Xin Yong Zhong He[5]. - The company has not disclosed any special arrangements for corporate governance or other significant matters[9]. - The company emphasizes that forward-looking statements regarding its planning and development strategies do not constitute substantive commitments to investors[7]. - The company has a diverse board with independent directors and various management roles, ensuring governance compliance[185]. - The company has established specialized committees to enhance governance and oversight functions[199]. - The audit committee approved the annual financial report for 2023 and the budget for 2024, all with unanimous votes[200]. - The company has not faced any penalties from securities regulatory agencies in the past three years[196]. Market and Industry Trends - The global pharmaceutical market is projected to grow from $1,100.2 billion in 2015 to $1,569.5 billion in 2023, with a compound annual growth rate (CAGR) of 8.6% for biopharmaceuticals, outpacing the 3.5% CAGR for chemical drugs[73]. - The Chinese biopharmaceutical market size reached approximately RMB 1.8 trillion in 2023, with a compound annual growth rate (CAGR) of 14.4% for biological drugs from 2015 to 2023, significantly outpacing the 2.1% CAGR for chemical drugs[74]. - The Chinese human vaccine market grew from RMB 53.5 billion in 2019 to RMB 120.5 billion in 2023, representing a CAGR of 22.5%, and is expected to reach RMB 343.1 billion by 2032, with a projected CAGR of 12.3% from 2023 to 2032[76]. - The overall success rate for biological drugs from Phase I clinical trials to commercialization is 11.5%, compared to 6.2% for chemical drugs, indicating a higher clinical success rate for innovative biological products[78]. - The integration of AI technology is transforming various stages of biopharmaceutical R&D, indicating a shift towards more advanced and efficient development processes[75]. Risk Management - There are no significant risks that could materially affect the company's operations during the reporting period[4]. - The company is actively enhancing its risk management system to address macroeconomic risks, including geopolitical tensions and trade frictions, which may impact international business operations[127]. - The company faces operational risks related to insufficient working capital due to ongoing R&D investments and potential challenges in equity and debt financing[124]. - The company acknowledges the competitive landscape in the biopharmaceutical industry, necessitating continuous innovation and technology tracking[119]. - The company faces risks of significant revenue decline or losses due to market competition and the performance of newly launched products[115]. Future Outlook - The company plans to strengthen its international strategy and supply chain resilience to better compete in the global market for innovative drugs[87]. - The company anticipates achieving profitability in 2024 through cost control and improved R&D efficiency[129]. - The company plans to continue investing in R&D and enhancing market promotion for existing products, which may lead to uncertainties in future revenue growth[113]. - The company aims to improve operational efficiency through enhanced internal controls and financial management practices[186]. - The company plans to implement a "quality improvement and efficiency return" action plan for 2024[197].

北京神州细胞生物技术集团股份公司 董事会议事规则 第一条 宗旨 为了进一步规范本公司董事会的议事方式和决策程序，促使董事和董事会有 效地履行其职责，提高董事会规范运作和科学决策水平，根据《中华人民共和国 公司法》《中华人民共和国证券法》《上市公司治理准则》《上海证券交易所科 创板股票上市规则》（以下简称"《上市规则》"）等法律法规、规范性文件和 《北京神州细胞生物技术集团股份公司章程》（以下简称"《公司章程》"）的规 定，制定本规则。 第二条 证券部 董事会下设证券部，处理董事会日常事务。 董事会秘书兼任证券部负责人，保管董事会和证券部印章。 第三条 定期会议 董事会会议分为定期会议和临时会议。 董事会每年至少召开两次定期会议，并应根据《公司章程》或者本规则规定 召开临时会议。 第四条 定期会议的提案 在发出召开董事会定期会议的通知前，证券部应当充分征求各董事的意见， 初步形成会议提案后交董事长拟定。 董事长在拟定提案前，应当视需要征求总经理和其他高级管理人员的意见。 第五条 临时会议 1 有下列情形之一的，董事会应当召开临时会议： 第六条 临时会议的提议程序 第七条 会议的召集和主持 董事会会议由董事长召集 ...